Alnylam Shares Rise After Strong 2Q, FDA Fast Track Designation

Dow Jones

2025/08/01

By Josh Beckerman

Shares of Alnylam Pharmaceuticals hit a 52-week high after it posted a strong quarter and said a heart-disease treatment received Food and Drug Administration Fast Track Designation.

The stock was up 16%, to $394.20, midday Thursday, with an intraday high of $402.43. Shares are up about 68% this year.

The Cambridge, Mass., company said the FDA awarded Fast Track Designation to nucresiran, a treatment for cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis.

Alnylam reported that second-quarter net product revenue rose 64%, to $672 million, with total revenue up 17%, to $773.7 million. The company increased its full-year net product revenue guidance range to $2.65 billion to $2.8 billion from $2.05 billion to $2.25 billion.

Adjusted earnings per share declined to 32 cents from 56 cents, but were above the average estimate of 2 cents from analysts polled by FactSet. The company posted higher expenses for sales, general and administrative costs as well as research and development.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 31, 2025 14:10 ET (18:10 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2556830753"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556830753\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556830753?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 02:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556830753","market":"sg","top_or_hot":-1,"title":"Alnylam Shares Rise After Strong 2Q, FDA Fast Track Designation","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ALNY\">Alnylam Pharmaceuticals</a> hit a 52-week high after it posted a strong quarter and said a heart-disease treatment received Food and Drug Administration <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation. \n</p>\n<p>\n  The stock was up 16%, to $394.20, midday Thursday, with an intraday high of $402.43. Shares are up about 68% this year. \n</p>\n<p>\n  The Cambridge, Mass., company said the FDA awarded Fast Track Designation to nucresiran, a treatment for cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis. \n</p>\n<p>\n  Alnylam reported that second-quarter net product revenue rose 64%, to $672 million, with total revenue up 17%, to $773.7 million. The company increased its full-year net product revenue guidance range to $2.65 billion to $2.8 billion from $2.05 billion to $2.25 billion. \n</p>\n<p>\n  Adjusted earnings per share declined to 32 cents from 56 cents, but were above the average estimate of 2 cents from analysts polled by FactSet. The company posted higher expenses for sales, general and administrative costs as well as research and development. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 31, 2025 14:10 ET (18:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam Shares Rise After Strong 2Q, FDA Fast Track Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam Shares Rise After Strong 2Q, FDA Fast Track Designation\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-08-01 02:10</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ALNY\">Alnylam Pharmaceuticals</a> hit a 52-week high after it posted a strong quarter and said a heart-disease treatment received Food and Drug Administration <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation. \n</p>\n<p>\n  The stock was up 16%, to $394.20, midday Thursday, with an intraday high of $402.43. Shares are up about 68% this year. \n</p>\n<p>\n  The Cambridge, Mass., company said the FDA awarded Fast Track Designation to nucresiran, a treatment for cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis. \n</p>\n<p>\n  Alnylam reported that second-quarter net product revenue rose 64%, to $672 million, with total revenue up 17%, to $773.7 million. The company increased its full-year net product revenue guidance range to $2.65 billion to $2.8 billion from $2.05 billion to $2.25 billion. \n</p>\n<p>\n  Adjusted earnings per share declined to 32 cents from 56 cents, but were above the average estimate of 2 cents from analysts polled by FactSet. The company posted higher expenses for sales, general and administrative costs as well as research and development. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 31, 2025 14:10 ET (18:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2556830753","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556830753","pubTimestamp":1753985400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Alnylam Pharmaceuticals hit a 52-week high after it posted a strong quarter and said a heart-disease treatment received Food and Drug Administration Fast Track Designation.The stock was up 16%, to $394.20, midday Thursday, with an intraday high of $402.43. Shares are up about 68% this year.The Cambridge, Mass., company said the FDA awarded Fast Track Designation to nucresiran, a treatment for cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis.Alnylam reported that second-quarter net product revenue rose 64%, to $672 million, with total revenue up 17%, to $773.7 million. The company increased its full-year net product revenue guidance range to $2.65 billion to $2.8 billion from $2.05 billion to $2.25 billion.Adjusted earnings per share declined to 32 cents from 56 cents, but were above the average estimate of 2 cents from analysts polled by FactSet. The company posted higher expenses for sales, general and administrative costs as well as research and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","ALNY":"阿尔尼拉姆制药公司","BK4548":"巴美列捷福持仓","FAST":"快扣","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4104":"贸易公司与经销商","BK4567":"ESG概念","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","BK4139":"生物科技"},"translate_title":"Alnylam股价在第二季度强劲并获得FDA快速通道指定后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FAST":1,"ALNY":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares of Alnylam Pharmaceuticals hit a 52-week high after it posted a strong quarter and said a heart-disease treatment received Food and Drug Administration Fast Track Designation. \n\n\n  The stock was up 16%, to $394.20, midday Thursday, with an intraday high of $402.43. Shares are up about 68% this year. \n\n\n  The Cambridge, Mass., company said the FDA awarded Fast Track Designation to nucresiran, a treatment for cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis. \n\n\n  Alnylam reported that second-quarter net product revenue rose 64%, to $672 million, with total revenue up 17%, to $773.7 million. The company increased its full-year net product revenue guidance range to $2.65 billion to $2.8 billion from $2.05 billion to $2.25 billion. \n\n\n  Adjusted earnings per share declined to 32 cents from 56 cents, but were above the average estimate of 2 cents from analysts polled by FactSet. The company posted higher expenses for sales, general and administrative costs as well as research and development. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 31, 2025 14:10 ET (18:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}